Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42566 | 0.85 | — | — | |
| SCHEMBL1489852 | 0.77 | DRD2 (0.34) | DRD2SIGMAR1DRD3 | |
| SCHEMBL19546253 | 0.77 | DRD2 (0.52) | DRD2SIGMAR1DRD3GNAI3GNAO1 | |
| SCHEMBL681521 | 0.77 | — | — | |
| SCHEMBL1046369 | 0.77 | DRD2 (0.52) | DRD2SIGMAR1DRD3GNAI3GNAO1 | |
| SCHEMBL384210 | 0.77 | DRD2 (0.52) | DRD2SIGMAR1DRD3GNAI3GNAO1 | |
| SCHEMBL6512381 | 0.77 | DRD2 (0.52) | DRD2SIGMAR1DRD3GNAI3GNAO1 | |
| SCHEMBL6659994 | 0.74 | DRD2 (0.50) | DRD2SIGMAR1DRD3GNAI3GNAO1 | |
| Ammonia Solution, Strong SCHEMBL9858529 | 0.74 | — | — | |
| Bromide SCHEMBL6660052 | 0.72 | DRD2 (0.48) | DRD2SIGMAR1DRD3GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | DRD2 2797/4885SIGMAR1 4345/4885SLC2A1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.